大腸癌新藥介紹：Braftovi®

New Drugs for the Treatment of Colorectal Cancer: Braftovi®

10.6880/TJON.202012_20(2).02

王嘉宏(Jia-Hong Wang)

大腸癌 ； BRAF抑制劑 ； 轉移性疾病 ； colorectal cancer ； BRAF inhibitors ； metastatic disease

腫瘤護理雜誌

20卷2期（2020 / 12 / 01）

11 - 15

繁體中文

大腸癌是全球第三大被診斷為男女性別的癌症，男性發病率僅次於肺癌和乳腺癌，是僅次於肺癌、肝癌和胃癌的第四大癌症死亡原因。使用5-fluorouracil（5-FU）、irinotecan和oxaliplatin三種組合，合併bevacizumab當作第一線治療BRAF突變的轉移性（metastatic colorectal cancer, mCRC）病人而預後不好時，美國食品藥品監督管理局（FDA）核准第二代BRAF抑制劑Braftovi®（encorafenib）合併使用Erbitux®（cetuximab）於治療具有BRAF V600E突變的轉移性結直腸癌（mCRC）的成人病人。最常見的副作用為疲勞、貧血、肌酸磷酸激酶升高、AST升高和尿路感染。藥物動力學方面：Braftovi®的最高血漿濃度的時間（Tmax）為2小時且至少86%的劑量被吸收，半衰期（t1/2）為3.5小時。

Colorectal cancer is the third most common cancer in the world. The incidence rate of men is second only to lung cancer and breast cancer, and is the fourth leading cause of cancer death after lung cancer, liver cancer and gastric cancer. When using the three combinations of 5-fluorouracil (5-FU), irinotecan and oxaliplatin, combined with bevacizumab as the first-line treatment of BRAF mutation metastatic colorectal cancer (mCRC) patients, the prognosis is not good. The U.S. Food and Drug Administration ( FDA) approved the second-generation BRAF inhibitor Braftovi®(encorafenib) combined with Erbitux®(cetuximab) for the treatment of adult patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The most common side effects are fatigue, anemia, increased creatine phosphokinase, increased AST, and urinary tract infections. Pharmacokinetics: The time (Tmax) of the highest plasma concentration of Braftov® is 2 hours and at least 86% of the dose is absorbed and the half-life (t1/2) is 3.5 hours.

1. Braftovi
2. Choong, M. K.,Tsafnat, G.(2012).Genetic and epigenetic biomarkers of colorectal cancer.Clinical Gastroenterology and Hepatology,10(1),9-15.
3. Ducreux, M.,Chamseddine, A.,Laurent-Puig, P.,Smolenschi, C.,Hollebecque, A.,Dartigues, P.,Gelli, M.(2019).Molecular targeted therapy of BRAF-mutant colorectal cancer.Therapeutic Advances in Medical Oncology,11,1758835919856494.
4. Ferlay, J.,Soerjomataram, I.,Dikshit, R.,Eser, S.,Mathers, C.,Rebelo, M.,Bray, F.(2015).Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.International Journal of Cancer,136(5),E359-E386.
5. Samalin, E.,Bouche, O.,Thézenas, S.,Francois, E.,Adenis, A.,Bennouna, J.,Galais, M. P.(2014).Sorafenib and irinotecan (NEXIRI) as second-or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: A multicentre Phase I/II trial.British Journal of Cancer,110(5),1148-1154.
6. Sánchez-Gundín, J.,Fernández-Carballido, A. M.,Martínez-Valdivieso, L.,Barreda-Hernández, D.,Torres-Suárez, A. I.(2018).New trends in the therapeutic approach to metastatic colorectal cancer.International journal of Medical Sciences,15(7),659-665.
7. Van Cutsem, E.,Montagut Viladot, C.,Tabernero Cartula, J.(2019).Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON colorectal cancer study.American Society of Clinical Oncology,37(17),1460-1469.
8. 郭朝禎(2012)。治療大腸直腸癌基因檢測得先來。科學發展，477。
9. 衛生福利部國民健康署（2020，11月2日）．大腸癌防治概況．取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=615&pid=1126
10. 鄭吉元,蔡慈貞(2018)。轉移性大腸直腸癌的藥物治療策略。藥學雜誌，34(1)，23-32。

1. 黃雅君,梁天麗(2021)。運用Swanson關懷理論於一位癌末病人死亡焦慮之護理經驗。榮總護理，38(4)，429-435。